Every 10-Q that Neurocrine Biosciences Inc (NBIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NBIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NBIX filings page.
Neurocrine Biosciences reported sharply stronger Q1 2026 results, with net income of $197.9 million and diluted EPS of $1.91, up from $0.08 a year earlier.
Total revenues rose to $814.5 million from $572.6 million, driven by INGREZZA net product sales of $656.9 million and CRENESSITY net product sales of $153.3 million as demand and new prescriptions grew. Operating income increased to $193.4 million, helped by a $28.6 million gain on the sale of Neurocrine Group Limited and higher investment and equity gains.
Neurocrine ended the quarter with $2.65 billion in cash, cash equivalents and marketable securities and generated $145.8 million of operating cash flow, while repurchasing $56.0 million of stock. The company agreed to acquire Soleno Therapeutics for approximately $2.9 billion in cash and expects to fund the deal with cash and investments, which will significantly reduce its cash balances.
Neurocrine Biosciences reported strong Q3 2025 results, with total revenues of $794.9 million, up from $622.1 million a year ago. Growth was driven by INGREZZA net product sales of $686.6 million and the U.S. launch of CRENESSITY contributing $98.1 million. Operating income was $239.0 million and net income reached $209.5 million, translating to diluted EPS of $2.04 versus $1.24 last year.
The company continued to invest for growth: research and development expense rose to $250.0 million and selling, general, and administrative expense to $291.6 million. Year to date, cash flows from operating activities were $394.3 million. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $2,113.3 million, with working capital of $1,520.4 million. Neurocrine repurchased 1.8 million shares for $227.2 million during the first nine months of 2025 under its $500 million authorization and completed a $300 million accelerated repurchase begun in 2024. Shares outstanding were 99,705,698 as of October 21, 2025.